Lapatinib Ditosylate Monohydrate CAS 388082-78-8 Pite > 99.0% (HPLC)

Deskripsyon kout:

Non Chimik: Lapatinib Ditosylate Monohydrate

CAS: 388082-78-8

Pite:> 99.0% (HPLC)

Aparans: Pale jòn poud jòn cristalline

Kontakte: Dr Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Lapatinib Entèmedyè:

Baz Lapatinib	CAS 231277-92-2
Lapatinib ditosylate monoidrat	CAS 388082-78-8
Methanesulfinate sodyòm	CAS 20277-69-4
3-Chloro-4-(3-Fluorobenzyloxy)anilin	CAS 202197-26-0
2-Aminoethyl Methyl Sulfon Hydrochloride	CAS 104458-24-4
4-Chloro-6-Iodoquinazoline	CAS 98556-31-1
6-Iodo-4-Hydroxyquinazoline	CAS 16064-08-7
5-Formil-2-furanboronik asid	CAS 27329-70-0
5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde	CAS 231278-84-5

Pwopriyete chimik:

Non Chimik	Lapatinib ditosylate monoidrat
Sinonim	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
Nimewo CAS	388082-78-8
Estati Stock	Nan stok
Fòmil molekilè	C29H26ClFN4O4S·2(C7H8O3S)·H2O
Pwa molekilè	943,48
COA & MSDS	Disponib
Orijin	Shanghai, Lachin
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Pale jòn poud jòn kristalin
Pite / Metòd analiz	≥99.0% (HPLC)
Pwen k ap fonn	240.0 ~ 242.0 ℃
Imidite (KF)	1.9 ~ 2.4%
Single enpurte	≤0.50%
Enpurte total	≤1.00%
Metal lou (tankou Pb)	≤20ppm
Tès Creole	Enterprise Standard
Itilizasyon	API;Pou tretman pasyan ki gen kansè nan tete

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

388082-78-8 - Aplikasyon:

Lapatinib Ditosylate Monohydrate (CAS: 388082-78-8) se sèl ditosylate nanCAS 231277-92-2, yon sentetik, oral-aktif quinazoline ak potansyèl aktivite antineoplastic.Li revèsibl bloke fosforilasyon reseptè faktè kwasans epidèm (EGFR), ErbB2, ak Erk-1 ak-2 ak AKT kinaz yo;li tou inibit nivo pwoteyin cyclin D nan liy selil timè imen ak xenografts.EGFR ak ErbB2 yo te enplike nan kwasans divès kalite timè.Li te lanse pou tretman kansè nan tete pozitif HER2 (ErbB2) avanse oswa metastatik nan fanm ki te resevwa terapi anvan.GlaxoSmithKline te dekouvri epi devlope dwòg la.